Aqualung Launches All New XSCAPE Collection Featuring Eco-Responsible Wetsuit
27.4.2021 12:00:00 EEST | Business Wire | Press release
Aqualung, the leading global designer and manufacturer of dive and water sports gear, today announced the launch of its all new XSCAPE collection. Featuring a 100 percent neoprene-free wetsuit and a rash guard made from sustainable materials, the XSCAPE line is designed for a variety of water activities and reflects Aqualung’s commitment to innovation, ocean discovery and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005227/en/
Aqualung launches all new XSCAPE collection featuring eco-responsible wetsuit. (Photo: Business Wire)
Made with Yulex® eco-friendly natural rubber and ultra-stretch fabric, the 4/3mm XSCAPE wetsuit provides enhanced comfort for diving in warm waters or above surface activities in colder temperatures, and can be used for scuba diving, snorkeling, freediving, paddling or a variety of other water sports. The flexible and lightweight XSCAPE wetsuit, available in a red and olive design for men and a tropical-inspired print for women, connects consumers to nature and the natural materials the collection is made from. The suit also features Powertex knee pads, recycled, quick-drying fleece around the torso area to provide additional warmth and comfort, and a reusable mesh bag for storage after use or collecting trash from the beach or water.
“The XSCAPE collection continues Aqualung's legacy in innovation, and their tireless work to create the most forward thinking and eco-conscious dive company in the world,” said Aqualung global ocean ambassador Philippe Cousteau Jr., the grandson of one of Aqualung’s original founders, Captain Jacques-Yves Cousteau. “We all have the power to change the world with the choices we make, and the XSCAPE sets the new standard for wetsuits and rash guards that are stylish, functional and sustainable.”
The new collection’s long-sleeve rash guard for men and women, and matching women’s leggings, offer maximum comfort and breathability and can be used above or below the surface. All rash guards and leggings feature UV protection and are made with polyester fabric sourced from recycled plastic bottles. The entire XSCAPE line comes in plastic-free packaging with hangtags made from recycled cardboard.
“Our aim was to design the ultimate eco-friendly wetsuit that could be used for all kinds of water sports,” said Laurent Boury, Senior Vice President of Brands at Aqualung Group. “Aqualung is committed to using environmentally-friendly materials and processes whenever possible to help reduce our carbon footprint, and we made design choices to ensure the XSCAPE collection was as sustainable as possible.”
“The collection name, XSCAPE, is meant to evoke the feeling of freedom and the quest for wonder that surround exploration, travel and Aqualung’s storied history, including the first ‘aqua-lung’ created by Captain Jacques-Yves Cousteau and engineer Emile Gagnan that made underwater exploration possible,” added Boury.
The XSCAPE collection is available at authorized Aqualung retailers. Inventory may vary by region. To learn more, please visit www.aqualung.com.
About Aqualung Brand
Aqualung, part of the Aqualung Group, is the leading global designer and manufacturer of dive and water sports gear. Now available in more than 100 countries around the world, Aqualung pioneered the creation of modern diving equipment when Captain Jacques-Yves Cousteau teamed with engineer Emile Gagnan in 1943 to develop the first “aqua-lung,” making underwater exploration possible. Aqualung is committed to providing sustainable, innovative, reliable, and easy-to-use products that allow adventure seekers to enjoy responsible water exploration and continues to set the industry standard for water sports equipment in technology, comfort, safety and design. For more information, visit www.aqualung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005227/en/
Contact information
Lauren Schuil
lschuil@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom